Researchers have been excited about Retatrutide , a innovative dual agonist showing remarkable data in clinical trials for size loss . It functions by targeting several pathways : GLP-1 and GIP, these, when retatrutide benefits engaged , support regulate cravings and enhance energy expenditure . Initial findings demonstrate noteworthy size reductio